The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Novo Nordisk said on Tuesday the U.S. FDA has approved its blockbuster drug Ozempic to lower the risk of progression of ...

Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients with chronic kidney disease and diabetes. Read more here.

Novo Nordisk (NVO) has reportedly been criticized by a U.K. pharma industry group for mischaracterizing certain payments to ...

We recently compiled a list of the 8 Best Socially Responsible Stocks to Buy According to Hedge Funds. In this article, we ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Novo Nordisk is doubling down on its collaboration ... focus to cover Novo’s defining indications—obesity and Type 2 diabetes—and increases the program cap to 20. If the programs hit their ...

Novo Nordisk provided significant funding to UK pharmacies for training, advertising and patient resources ... Compounding For Its Early-Generation Diabetes Drug Between 2021 and 2023, Novo ...

rendering these products less effective or ineffective for conditions such as type 2 diabetes, cardiovascular disease, and chronic weight management. Novo Nordisk also noted 44 documented adverse ...